Serum Selenium Level and 10-Year Survival after Melanoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Participants
2.2. Measurement of Selenium Level
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Vanella, V.; Festino, L.; Vitale, M.G.; Alfano, B.; Ascierto, P.A. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. Expert Opin. Emerg. Drugs 2021, 26, 79–92. [Google Scholar] [CrossRef]
- Lou-Qian, Z.; Rong, Y.; Ming, L.; Xin, Y.; Feng, J.; Lin, X. The Prognostic Value of Epigenetic Silencing of p16 Gene in NSCLC Patients: A Systematic Review and Meta-Analysis. PLoS ONE 2013, 8, e54970. [Google Scholar] [CrossRef] [PubMed]
- Short, S.; Williams, C.S. Selenoproteins in Tumorigenesis and Cancer Progression. Adv. Cancer Res. 2017, 136, 49–83. [Google Scholar] [CrossRef] [Green Version]
- Rayman, M.P. Selenium in cancer prevention: A review of the evidence and mechanism of action. In Proceedinds of the Nutrition Society; CABI Publishing: Oxfordshire, UK, 2005; Volume 64, pp. 527–542. [Google Scholar]
- Rayman, M.P. Selenium and human health. Lancet 2012, 379, 1256–1268. [Google Scholar] [CrossRef]
- Fernandes, A.P.; Gandin, V. Selenium compounds as therapeutic agents in cancer. Biochim. Biophys. Acta (BBA) Gen. Subj. 2015, 1850, 1642–1660. [Google Scholar] [CrossRef]
- Navarro Silvera, S.A.; Rohan, T.E. Trace elements and cancer risk: A review of the epidemiologic evidence. Cancer Causes Control CCC 2007, 18, 7–27. [Google Scholar] [CrossRef] [PubMed]
- Vinceti, M.; Filippini, T.; Del Giovane, C.; Dennert, G.; Zwahlen, M.; Brinkman, M.; Zeegers, M.; Horneber, M.; D’Amico, R.; Crespi, C. Selenium for preventing cancer. Cochrane Database Syst. Rev. 2018, 29, 1. [Google Scholar] [CrossRef]
- Avery, J.C.; Hoffmann, P.R. Selenium, Selenoproteins, and Immunity. Nutrients 2018, 1, 1203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vinceti, M.; Ballotari, P.; Steinmaus, C.; Malagoli, C.; Luberto, F.; Malavolti, M.; Rossi, P.G. Long-term mortality patterns in a residential cohort exposed to inorganic selenium in drinking water. Environ. Res. 2016, 150, 348–356. [Google Scholar] [CrossRef]
- Cassidy, P.B.; Fain, H.D.; Cassidy, J.J.P.; Tran, S.M.; Moos, P.J.; Boucher, K.M.; Gerads, R.; Florell, S.R.; Grossman, D.; Leachman, S.A. Selenium for the Prevention of Cutaneous Melanoma. Nutrients 2013, 5, 725–749. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garland, M.; Morris, J.S.; Stampfer, M.J.; Colditz, G.A.; Spate, V.L.; Baskett, C.K.; Rosner, B.; Speizer, F.E.; Willett, W.C.; Hunter, D.J. Prospective Study of Toenail Selenium Levels and Cancer Among Women. J. Natl. Cancer Inst. 1995, 87, 497–505. [Google Scholar] [CrossRef] [PubMed]
- Asgari, M.M.; Maruti, S.S.; Kushi, L.H.; White, E. Antioxidant supplementation and risk of incident melanomas: Results of a large prospective cohort study. Arch. Dermatol. 2009, 145, 879–882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Le Marchand, L.; Saltzman, B.S.; Hankin, J.H.; Wilkens, L.R.; Franke, A.A.; Morris, S.J.; Kolonel, L.N. Sun exposure, diet, and melanoma in Hawaii Caucasians. Am. J. Epidemiol. 2006, 164, 232–245. [Google Scholar]
- Breslow, R.A.; Alberg, A.J.; Helzlsouer, K.J.; Bush, T.L.; Norkus, E.P.; Morris, J.S.; Spate, V.E.; Comstock, G.W. Serological precursors of cancer: Malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta- carotene, lycopene, alpha-tocopherol, and selenium. Cancer Epidemiol. Biomark. Prev. 1995, 4, 4. [Google Scholar]
- Vinceti, M.; Crespi, C.M.; Malagoli, C.; Bottecchi, I.; Ferrari, A.; Sieri, S.; Krogh, V.; Alber, D.; Bergomi, M.; Seidenari, S.; et al. A case-control study of the risk of cutaneous melanoma associated with three selenium exposure indicators. Tumori. J. 2012, 98, 287–295. [Google Scholar] [CrossRef] [Green Version]
- Vinceti, M.; Vicentini, M.; Wise, L.; Sacchettini, C.; Malagoli, C.; Ballotari, P.; Filippini, T.; Malavolti, M.; Rossi, P.G. Cancer incidence following long-term consumption of drinking water with high inorganic selenium content. Sci. Total. Environ. 2018, 635, 390–396. [Google Scholar] [CrossRef]
- Matthews, N.H.; Fitch, K.; Li, W.-Q.; Morris, J.S.; Christiani, D.C.; Qureshi, A.A.; Cho, E. Exposure to Trace Elements and Risk of Skin Cancer: A Systematic Review of Epidemiologic Studies. Cancer Epidemiol. Biomark. Prev. 2019, 28, 3–21. [Google Scholar] [CrossRef] [Green Version]
- Rayman, M.P. Selenium intake, status, and health: A complex relationship. Hormones 2020, 19, 9–14. [Google Scholar] [CrossRef] [Green Version]
- Chen, T.; Wong, Y.S. Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell. Mol. Life Sci. 2008, 65, 2763–2775. [Google Scholar] [CrossRef] [PubMed]
- Chen, T.; Wong, Y.-S. Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation. Int. J. Biochem. Cell Biol. 2009, 41, 666–676. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.-C.; Prabhu, K.S.; Mastro, A.M. Is Selenium a Potential Treatment for Cancer Metastasis? Nutrients 2013, 5, 1149–1168. [Google Scholar] [CrossRef] [Green Version]
- Poerschke, R.L.; Moos, P.J. Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction. Biochem. Pharmacol. 2011, 81, 211–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sá, I.; Nogueira, T.; Cunha, E. The Effects of Lead and Selenium on Melanoma Induction. Int. J. Med. Stud. 2015, 3, 83–87. [Google Scholar] [CrossRef]
- Evans, S.; Khairuddin, P.F.; Jameson, M.B. Optimising Selenium for Modulation of Cancer Treatments. Anticancer. Res. 2017, 37, 6497–6509. [Google Scholar] [CrossRef] [Green Version]
- Jönsson-Videsäter, K.; Björkhem-Bergman, L.; Hossain, A.; Söderberg, A.; Eriksson, L.C.; Paul, C.; Rosén, A.; Björnstedt, M. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem. Pharmacol. 2004, 67, 513–522. [Google Scholar] [CrossRef]
- Schott, M.; De Jel, M.M.; Engelmann, J.C.; Renner, P.; Geissler, E.K.; Bosserhoff, A.; Kuphal, S. Selenium-binding protein 1 is down-regulated in malignant melanoma. Oncotarget 2018, 9, 10445–10456. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marciel, M.P.; Khadka, V.S.; Deng, Y.; Kilicaslan, P.; Pham, A.; Bertino, P.; Lee, K.; Chen, S.; Glibetic, N.W.; Hoffmann, F.; et al. Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis. Oncotarget 2018, 9, 13407–13422. [Google Scholar] [CrossRef] [Green Version]
- Davis, C.D.; Tsuji, P.A.; Milner, J.A. Selenoproteins and Cancer Prevention. Annu. Rev. Nutr. 2012, 32, 73–95. [Google Scholar] [CrossRef] [PubMed]
- Steinbrenner, H.; Speckmann, B.; Sies, H. Toward Understanding Success and Failures in the Use of Selenium for Cancer Prevention. Antioxid. Redox Signal. 2013, 19, 181–191. [Google Scholar] [CrossRef] [PubMed]
- Harris, H.R.; Bergkvist, L.; Wolk, A. Selenium intake and breast cancer mortality in a cohort of Swedish women. Breast Cancer Res. Treat. 2012, 134, 1269–1277. [Google Scholar] [CrossRef] [PubMed]
- Sandsveden, M.; Nilsssson, E.; Borgquist, S.; Rosendahl, A.H.; Manjer, J. Prediagnostic serum selenium levels in relation to breast cancer survival and tumor characteristics. Int. J. Cancer 2020, 147, 2424–2436. [Google Scholar] [CrossRef]
- Szwiec, M.; Marciniak, W.; Derkacz, R.; Huzarski, T.; Gronwald, J.; Cybulski, C.; Dębniak, T.; Jakubowska, A.; Lener, M.; Falco, M.; et al. Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. Nutrients 2021, 13, 953. [Google Scholar] [CrossRef] [PubMed]
- Lubinski, J.; Marciniak, W.; Muszynska, M.; Huzarski, T.; Gronwald, J.; Cybulski, C.; Jakubowska, A.; Debniaket, T.; Falco, M.; Kladny, J.; et al. Serum selenium levels predict survival after breast cancer. Breast Cancer Res. Treat. 2018, 167, 591–598. [Google Scholar] [CrossRef] [PubMed]
- Pietrzak, S.; Wójcik, J.; Scott, R.J.; Kashyap, A.; Grodzki, T.; Baszuk, P.; Bielewicz, M.; Marciniak, W.; Wójcik, N.; Dębniak, T.; et al. Influence of the selenium level on overall survival in lung cancer. J. Trace Elem. Med. Biol. 2019, 56, 46–51. [Google Scholar] [CrossRef]
- Lubiński, J.; Marciniak, W.; Muszyńska, M.; Jaworowska, E.; Sulikowski, M.; Jakubowska, A.; Kaczmarek, K.; Sukiennicki, G.; Falco, M.; Baszuk, P.; et al. Correction: Serum selenium levels and the risk of progression of laryngeal cancer. PLoS ONE 2018, 13, e0194469. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Characteristic | Overall, n = 375 1 | Alive, n = 344 1 | Deceased, n = 31 1 |
---|---|---|---|
Selenium level in quartiles (µg/L) | |||
I (56.68–76.23) | 94 (25%) | 78 (23%) | 16 (52%) |
II (76.44–85.01) | 93 (25%) | 86 (25%) | 7 (23%) |
III (85.15–96.06) | 94 (25%) | 88 (26%) | 6 (19%) |
IV (96.15–168.01) | 94 (25%) | 92 (27%) | 2 (6.5%) |
Sex | |||
Female | 232 (62%) | 218 (63%) | 14 (45%) |
Male | 143 (38%) | 126 (37%) | 17 (55%) |
Age | 21.00–90.00 (54.63) | 21.00–90.00 (53.76) | 38.00–86.00 (64.26) |
Breslow (mm) * | 0.20–16.80 (1.80) | 0.20–16.80 (1.71) | 0.50–11.00 (3.22) |
Clark II | 71 (19%) | 70 (20%) | 1 (3.2%) |
Clark III | 157 (42%) | 145 (42%) | 12 (39%) |
Clark IV/V | 147 (39%) | 129 (38%) | 18 (58%) |
Subgroup | Level | n | Mean | SD | Median | Min | Max | Range | IQR |
---|---|---|---|---|---|---|---|---|---|
Sex | |||||||||
Female | 232 | 88.29 | 18.15 | 85.25 | 56.68 | 168.01 | 111.33 | 19.48 | |
Male | 143 | 87.29 | 16.83 | 84.46 | 58.17 | 162.96 | 104.79 | 19.59 | |
Clark | |||||||||
II | 71 | 92.77 | 19.35 | 89.99 | 62.61 | 168.01 | 105.4 | 16.93 | |
III | 157 | 88.78 | 18.43 | 84.51 | 57.72 | 166.08 | 108.36 | 21.78 | |
IV/V | 147 | 84.63 | 15.22 | 82.16 | 56.68 | 143.66 | 86.98 | 19.82 | |
Selenium level in quartiles (µg/L) | |||||||||
I | 94 | 69.99 | 5.2 | 71.94 | 56.68 | 76.23 | 19.55 | 6.47 | |
II | 93 | 80.62 | 2.69 | 80.96 | 76.44 | 85.01 | 8.56 | 5.08 | |
III | 94 | 90.29 | 3.31 | 90.19 | 85.15 | 96.06 | 10.91 | 6.42 | |
IV | 94 | 110.66 | 17.3 | 102.57 | 96.15 | 168.01 | 71.87 | 17.24 |
Univariable Cox Regression | Multivariable Cox Regression | |||||
---|---|---|---|---|---|---|
Characteristic | HR 1 | 95% CI 1 | p-Value | HR 1 | 95% CI 1 | p-Value |
Selenium level in quartiles (µg/L) | ||||||
I (56.68–76.23) | 8.42 | 1.94, 36.6 | 0.005 | 5.83 | 1.32, 25.8 | 0.020 |
II (76.44–85.01) | 3.73 | 0.77, 18.0 | 0.10 | 3.37 | 0.70, 16.3 | 0.13 |
III (85.15–96.06) | 3.05 | 0.62, 15.1 | 0.2 | 3.34 | 0.67, 16.7 | 0.14 |
IV (96.15–168.01) | — | — | — | — | ||
Sex | ||||||
Female | — | — | — | — | ||
Male | 2.12 | 1.05, 4.31 | 0.037 | 1.58 | 0.77, 3.27 | 0.2 |
Age | 1.06 | 1.03, 1.09 | <0.001 | 1.05 | 1.02, 1.08 | 0.002 |
Breslow (mm) * | 1.16 | 1.04, 1.29 | 0.008 | 1.10 | 0.96, 1.27 | 0.2 |
Clark II | — | — | — | — | ||
Clark III | 5.47 | 0.71, 42.1 | 0.10 | 3.94 | 0.50, 31.0 | 0.2 |
Clark IV/V | 8.76 | 1.17, 65.7 | 0.035 | 5.11 | 0.67, 39.3 | 0.12 |
Univariable Cox Regression | Multivariable Cox Regression | |||||
---|---|---|---|---|---|---|
Characteristic | HR1 | 95% CI 1 | p-Value | HR 1 | 95% CI 1 | p-Value |
Selenium level in quartiles (µg/L) | ||||||
I (56.68-76.23) | 10.6 | 1.35, 82.5 | 0.025 | 7.26 | 0.90, 58.3 | 0.062 |
II (76.44–85.01) | 5.33 | 0.62, 45.6 | 0.13 | 4.92 | 0.57, 42.7 | 0.15 |
III (85.15- 96.06) | 4.17 | 0.47, 37.3 | 0.2 | 4.97 | 0.54, 45.4 | 0.2 |
IV (96.15–168.01) | — | — | — | — | ||
Sex | ||||||
Female | — | — | — | — | ||
Male | 1.55 | 0.64, 3.75 | 0.3 | 1.16 | 0.47, 2.87 | 0.7 |
Age | 1.06 | 1.02, 1.10 | 0.002 | 1.05 | 1.01, 1.09 | 0.017 |
Breslow (mm) | 1.16 | 1.04, 1.29 | 0.008 | 1.10 | 0.96, 1.27 | 0.2 |
Clark | ||||||
II | — | — | — | — | ||
III | 3.90 | 0.49, 30.8 | 0.2 | 3.22 | 0.40, 26.1 | 0.3 |
IV/V | 5.11 | 0.65, 40.0 | 0.12 | 2.44 | 0.28, 21.2 | 0.4 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rogoża-Janiszewska, E.; Malińska, K.; Baszuk, P.; Marciniak, W.; Derkacz, R.; Lener, M.; Jakubowska, A.; Cybulski, C.; Huzarski, T.; Masojć, B.; et al. Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines 2021, 9, 991. https://doi.org/10.3390/biomedicines9080991
Rogoża-Janiszewska E, Malińska K, Baszuk P, Marciniak W, Derkacz R, Lener M, Jakubowska A, Cybulski C, Huzarski T, Masojć B, et al. Serum Selenium Level and 10-Year Survival after Melanoma. Biomedicines. 2021; 9(8):991. https://doi.org/10.3390/biomedicines9080991
Chicago/Turabian StyleRogoża-Janiszewska, Emilia, Karolina Malińska, Piotr Baszuk, Wojciech Marciniak, Róża Derkacz, Marcin Lener, Anna Jakubowska, Cezary Cybulski, Tomasz Huzarski, Bartłomiej Masojć, and et al. 2021. "Serum Selenium Level and 10-Year Survival after Melanoma" Biomedicines 9, no. 8: 991. https://doi.org/10.3390/biomedicines9080991